CY1105364T1 - Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης - Google Patents

Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης

Info

Publication number
CY1105364T1
CY1105364T1 CY20061100716T CY061100716T CY1105364T1 CY 1105364 T1 CY1105364 T1 CY 1105364T1 CY 20061100716 T CY20061100716 T CY 20061100716T CY 061100716 T CY061100716 T CY 061100716T CY 1105364 T1 CY1105364 T1 CY 1105364T1
Authority
CY
Cyprus
Prior art keywords
methods
compositions
immune modulation
protein
disclosed
Prior art date
Application number
CY20061100716T
Other languages
English (en)
Inventor
Reginald M. Gorczynski
David A. Clark
Original Assignee
Trillium Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22058127&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105364(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trillium Therapeutics Inc. filed Critical Trillium Therapeutics Inc.
Publication of CY1105364T1 publication Critical patent/CY1105364T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

Κοινοποιούνται μέθοδοι και συνθέσεις για την επαγωγή ανοσοποιητικής ανταπόκρισης. Οι μέθοδοι περιλαμβάνουν την χορήγηση μιας αποτελεσματικής ποσότητας από πρωτεΐνη ΟΧ-2 ή ενός νουκλεϊκού οξέως (nucleic acid) που κωδικοποιεί μία πρωτεΐνη ΟΧ-2. Οι μέθοδοι είναι χρήσιμες για την παρεμπόδιση της απόρριψης μοσχεύματος, της απώλειας εμβρύου, της ασθένειας της αυτό-ανοσοποίησης και των αλλεργιών. Κοινοποιούνται επίσης μέθοδοι και συνθέσεις για την παρεμπόδιση της καταστολής ανοσοποίησης. Οι μέθοδοι περιλαμβάνουν την χορήγηση μιας αποτελεσματικής ποσότητας ενός παράγοντα που εμποδίζει το ΟΧ-2.
CY20061100716T 1997-11-07 2006-06-05 Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης CY1105364T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6476497P 1997-11-07 1997-11-07
PCT/CA1998/001038 WO1999024565A1 (en) 1997-11-07 1998-11-06 Methods and compositions for immunomodulation

Publications (1)

Publication Number Publication Date
CY1105364T1 true CY1105364T1 (el) 2010-03-03

Family

ID=22058127

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100716T CY1105364T1 (el) 1997-11-07 2006-06-05 Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης

Country Status (13)

Country Link
US (6) US6338851B1 (el)
EP (1) EP1032662B1 (el)
JP (2) JP4584447B2 (el)
AT (1) ATE319825T1 (el)
AU (1) AU748587B2 (el)
CA (1) CA2308765C (el)
CY (1) CY1105364T1 (el)
DE (1) DE69833779T2 (el)
DK (1) DK1032662T3 (el)
ES (1) ES2260852T3 (el)
HK (1) HK1030625A1 (el)
PT (1) PT1032662E (el)
WO (1) WO1999024565A1 (el)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032662B1 (en) 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
CA2369454A1 (en) * 1999-04-13 2000-10-19 Schering Corporation Uses of mammalian ox2 protein and related reagents
WO2001008700A1 (en) * 1999-07-28 2001-02-08 Genetics Institute, Inc. Preventing immune-mediated abortion by inhibiting costimulation
JP2003527400A (ja) 2000-03-17 2003-09-16 トランスプランテイション テクノロジーズ インコーポレイテッド 免疫調節のための方法および組成物
ES2292587T3 (es) * 2000-04-22 2008-03-16 Pharmedartis Gmbh Agentes apoptoticos.
CA2417874C (en) * 2000-08-03 2012-10-02 Transplantation Technologies Inc. Use of ox-2 inhibitors for the treatment of cancer
AUPR069500A0 (en) * 2000-10-11 2000-11-09 Coster, Douglas John Tissue modification
CA2429579A1 (en) 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
AU2002246632B2 (en) 2000-12-08 2007-04-05 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6906237B2 (en) * 2001-02-27 2005-06-14 G. Scott Herron Vivo assay for anti angiogenic compounds
WO2003014151A2 (en) 2001-08-10 2003-02-20 Genset S.A. Human secreted proteins, their encoding polynucleotides, and uses thereof
EP2316485A1 (en) * 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
US7196243B2 (en) 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
AU2003299823A1 (en) * 2002-12-27 2004-07-29 Schering Corporation Methods of inducing and maintaining immune tolerance
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
US7741038B2 (en) 2005-03-14 2010-06-22 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
GB0506721D0 (en) * 2005-04-01 2005-05-11 Univ Glasgow Soluble immunoregulatory factor
KR101459159B1 (ko) 2006-01-12 2014-11-12 알렉시온 파마슈티칼스, 인코포레이티드 Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도
WO2008085963A1 (en) * 2007-01-05 2008-07-17 University Of Florida Research Foundation, Inc. Materials and methods for the detection, prevention and treatment of autoimmune disease
KR20100041849A (ko) * 2007-07-25 2010-04-22 알렉시온 파마슈티칼스, 인코포레이티드 Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도
CA2694121C (en) 2007-07-25 2016-06-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
US9938579B2 (en) * 2009-01-15 2018-04-10 The Board Of Trustees Of The Leland Stanford Junior University Biomarker panel for diagnosis and prediction of graft rejection
CA2782803C (en) 2009-12-02 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
AU2011203879A1 (en) 2010-01-11 2012-08-02 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
AU2011215750A1 (en) 2010-02-11 2012-08-23 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-CD200 antibodies
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
ES2798114T3 (es) 2010-03-25 2020-12-09 Univ Leland Stanford Junior Biomarcadores de proteínas y de genes para el rechazo de trasplantes de órganos
EP2683742B1 (en) 2011-03-11 2018-12-19 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
BR112017012928A2 (pt) 2014-12-19 2018-05-15 Alexion Pharma Inc uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste
EP3370763B1 (en) * 2015-11-03 2024-04-10 Regents of the University of Minnesota Cd200 inhibitors and methods of use thereof
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
WO2019084682A1 (en) 2017-10-30 2019-05-09 Mcmaster University Methods for the diagnosis and treatment of endometriosis
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
GB9505653D0 (en) * 1995-03-21 1995-05-10 Shober Wharton Method of pest control
AU1144097A (en) * 1995-12-08 1997-07-03 Brigham And Women's Hospital Ox-2 costimulatory molecule
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
EP1032662B1 (en) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
JP2003527400A (ja) 2000-03-17 2003-09-16 トランスプランテイション テクノロジーズ インコーポレイテッド 免疫調節のための方法および組成物
CA2429579A1 (en) 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
US7368535B2 (en) 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
US7196243B2 (en) * 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery

Also Published As

Publication number Publication date
AU748587B2 (en) 2002-06-06
AU1017399A (en) 1999-05-31
US20020086011A1 (en) 2002-07-04
JP2010155846A (ja) 2010-07-15
US20020151485A1 (en) 2002-10-17
EP1032662A1 (en) 2000-09-06
DE69833779T2 (de) 2006-11-30
DK1032662T3 (da) 2006-07-03
JP4584447B2 (ja) 2010-11-24
JP2001522867A (ja) 2001-11-20
EP1032662B1 (en) 2006-03-08
HK1030625A1 (en) 2001-05-11
US20110206668A1 (en) 2011-08-25
US20090232825A1 (en) 2009-09-17
US7902151B2 (en) 2011-03-08
US6338851B1 (en) 2002-01-15
DE69833779D1 (de) 2006-05-04
ES2260852T3 (es) 2006-11-01
CA2308765A1 (en) 1999-05-20
PT1032662E (pt) 2006-07-31
WO1999024565A1 (en) 1999-05-20
US20020103151A1 (en) 2002-08-01
ATE319825T1 (de) 2006-03-15
US6984625B2 (en) 2006-01-10
US6749854B2 (en) 2004-06-15
CA2308765C (en) 2010-10-12
US6652858B2 (en) 2003-11-25

Similar Documents

Publication Publication Date Title
CY1105364T1 (el) Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης
MX9203379A (es) Proteinas producidas por los linfocitos humanos, secuencia de adn que codifica para estas proteinas y composiciones farmaceuticas que las contienen.
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
EP1009440A4 (en) METHODS OF INHIBITING RESPONSES ASSOCIATED WITH IMMUNOSTIMULATOR DNA
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
NO891818L (no) T4-reseptor-protein, relaterte dna-sekvenser samt fremstilling derav.
DK0914331T3 (da) Neuroaktive peptider
DE68929467D1 (de) HIV-2 Varianten
CY1109710T1 (el) Επιτοπα βοηθητικων τ λεμφοκυτταρων
NO885670D0 (no) Fortilsetning og for som inneholder denne tilsetning.
DE59710609D1 (de) Mittel zur Herstellung von Leder
DK317288A (da) Hybridprotein af humant protein c og dets fremstilling samt dna, som koder det
ES2079481T3 (es) Un procedimiento para la determinacion de la actividad funcional de la proteina s o de la proteina c libre en una muestra de plasma.
DE69022926D1 (de) Virtuelle Mikrophonanlage und dafür bestimmtes Verfahren.
IT8621222A0 (it) Procedimento di (co)polimerizzazione di alfa-olefine in presenza di antiossidanti.
NO913035L (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
DE3860646D1 (de) Thermoplastische siliconkautschukpfropfpolymerisate (i).
DE68910100D1 (de) Mittel zur Bluttrennung.
DE69015372D1 (de) Protein-testverfahren.
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
ES2012063B3 (es) Procedimiento mejorado para obtencion de p-cimeno y alquilbencenos homologos.
DK0588177T3 (da) Interferon-alpha/beta-bindende protein, fremstilling heraf samt farmaceutiske præparater indeholdende proteinet
DE68919463D1 (de) Bremsbackenführungselement und dieses verwendende Bremse.
PE20399A1 (es) Muteina ob